Superseded 7/1/2023)

Superseded 7/1/2023
26B-4-222.  Report.

(1)  By the November interim meeting each year beginning in 2020, the department shall report to the Health and Human Services Interim Committee on:

Terms Used In Utah Code 26B-4-222

  • Cannabis: means marijuana. See Utah Code 26B-4-201
  • Department: means the Department of Health and Human Services. See Utah Code 26B-4-201
  • Medical cannabis: means cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form. See Utah Code 26B-4-201
  • Medical cannabis pharmacy: means a person that:
(a) 
(i) acquires or intends to acquire medical cannabis or a cannabis product in a medicinal dosage form from a cannabis processing facility or another medical cannabis pharmacy or a medical cannabis device; or
(ii) possesses medical cannabis or a medical cannabis device; and
(b) sells or intends to sell medical cannabis or a medical cannabis device to a medical cannabis cardholder. See Utah Code 26B-4-201
  • State central patient portal: means the website the department creates, in accordance with Section 26B-4-236, to facilitate patient safety, education, and an electronic medical cannabis order. See Utah Code 26B-4-201
  • (a)  the number of applications and renewal applications filed for medical cannabis cards;

    (b)  the number of qualifying patients and designated caregivers;

    (c)  the nature of the debilitating medical conditions of the qualifying patients;

    (d)  the age and county of residence of cardholders;

    (e)  the number of medical cannabis cards revoked;

    (f)  the number of practitioners providing recommendations for qualifying patients;

    (g)  the number of license applications and renewal license applications received;

    (h)  the number of licenses the department has issued in each county;

    (i)  the number of licenses the department has revoked;

    (j)  the quantity of medical cannabis shipments that the state central patient portal facilitates;

    (k)  the number of overall purchases of medical cannabis and medical cannabis products from each medical cannabis pharmacy;

    (l)  the expenses incurred and revenues generated from the medical cannabis program; and

    (m)  an analysis of product availability in medical cannabis pharmacies.

    (2)  The report shall include information provided by the Center for Medical Cannabis Research described in Section 53B-17-1402.

    (3)  The department may not include personally identifying information in the report described in this section.

    (4)  During the 2022 legislative interim, the department shall report to the working group described in Section 36-12-8.2 as requested by the working group.

    Amended by Chapter 281, 2023 General Session
    Renumbered and Amended by Chapter 307, 2023 General Session